At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ABSI Absci Corporation.
Pre-Mkt 03-26 05:17:15 EDT
2.92
-0.09
-2.99%
盘前2.87
-0.05-1.71%
04:01 EDT
High3.11Low2.80Vol7.14M
Open2.90D1 Closing3.01Amplitude10.30%
Mkt Cap446.82MTradable Cap385.44MTotal Shares153.02M
T/O20.76MT/O Rate5.41%Tradable Shares132.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Absci Shares Fall 4.9% After Q4 Results
THOMSON REUTERS  ·  03-25 21:31
Absci Shares Fall 4.9% After Q4 Results
Absci, DigitalOcean And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Benzinga  ·  03-25 20:02
Absci, DigitalOcean And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Absci price target lowered to $4.20 from $4.32 at Morgan Stanley
TIPRANKS  ·  03-25 19:35
Absci price target lowered to $4.20 from $4.32 at Morgan Stanley
Absci Price Target Maintained With a $7.00/Share by Needham
Dow Jones  ·  03-25 19:15
Absci Price Target Maintained With a $7.00/Share by Needham
AbSci (ABSI) Gets a Buy from Guggenheim
TIPRANKS  ·  03-25 18:59
AbSci (ABSI) Gets a Buy from Guggenheim
Absci Corp : Morgan Stanley Cuts Target Price to $4.20 From $4.32
THOMSON REUTERS  ·  03-25 18:58
Absci Corp : Morgan Stanley Cuts Target Price to $4.20 From $4.32
Analysts Conflicted on These Healthcare Names: Fractyl Health, Inc. (GUTS), AbSci (ABSI) and Alnylam Pharma (ALNY)
TIPRANKS  ·  03-25 18:50
Analysts Conflicted on These Healthcare Names: Fractyl Health, Inc. (GUTS), AbSci (ABSI) and Alnylam Pharma (ALNY)
Absci Shares Fall on Wider 4Q Loss, Lower Revenue
Dow Jones  ·  03-25 18:36
Absci Shares Fall on Wider 4Q Loss, Lower Revenue
Absci Shares Fall 9% Premarket After Q4 Results
THOMSON REUTERS  ·  03-25 16:06
Absci Shares Fall 9% Premarket After Q4 Results
U.S. RESEARCH ROUNDUP-Amazon, Diamondback Energy, Matador Resources
Reuters  ·  03-25 16:01
U.S. RESEARCH ROUNDUP-Amazon, Diamondback Energy, Matador Resources
Absci Corp reports results for the quarter ended December 31 - Earnings Summary
Reuters  ·  03-25 05:52
Absci Corp reports results for the quarter ended December 31 - Earnings Summary
BRIEF-Absci Corp Q4 Revenue Was $0.7 Million
Reuters  ·  03-25 04:35
BRIEF-Absci Corp Q4 Revenue Was $0.7 Million
Absci Q4 EPS $(0.20), Inline, Sales $650.000K Miss $1.100M Estimate
Benzinga  ·  03-25 04:08
Absci Q4 EPS $(0.20), Inline, Sales $650.000K Miss $1.100M Estimate
AbSci Corp options imply 13.4% move in share price post-earnings
TIPRANKS  ·  03-25 02:05
AbSci Corp options imply 13.4% move in share price post-earnings
Absci Corp - Launches Endometriosis Advisory Board for Abs-201 Program
THOMSON REUTERS  ·  03-24 20:23
Absci Corp - Launches Endometriosis Advisory Board for Abs-201 Program
Absci launches ABS-201 endometriosis advisory board
Reuters  ·  03-24 20:01
Absci launches ABS-201 endometriosis advisory board
Top News Today/Canada: Bank of Canada to Lose Two Members of Rate-Setting Governing Council
Dow Jones  ·  03-24 04:30
Top News Today/Canada: Bank of Canada to Lose Two Members of Rate-Setting Governing Council
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones  ·  03-23 18:00
Calendar of U.S. Earnings Expected in the Week Ahead
Absci Corp expected to post a loss of 19 cents a share - Earnings Preview
Reuters  ·  03-21
Absci Corp expected to post a loss of 19 cents a share - Earnings Preview
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones  ·  03-20
Calendar of U.S. Earnings Expected in the Week Ahead
No data available

Introduction

Company Name.
Absci Corporation.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. It has a collaboration with Memorial Sloan Kettering Cancer Center to discover novel therapeutics using generative AI; with AstraZeneca PLC for AI-driven drug discovery against an oncology target; and with Twist Bioscience Corporation to design a novel therapeutic using generative AI. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Issue price:
--